Analysts at Maxim Group have initiated coverage of Momenta Pharmaceuticals, Inc. (MNTA) with a buy rating.
The firm set its price target on the stock at $24 a share, which is more than double its current market price.
Shares of MNTA are up 1% to $10.42 in the pre-market session, amid a 52-week trading range of $9.85 – $19.90.
Latest posts by Kevin Calderon (see all)
- First Gliding Mammals Were Contemporary With The Dinosaurs - Aug 14, 2017
- Jeanne Moreau, The Renowned French Actress, Dies At The Age Of 89 - Jul 31, 2017
- Netflix Now Has Over 100 Million Subscribers - Jul 19, 2017